Physician profile
John Mark Snyder
NPI 1003016304
$529.97
in general payments reported to CMS, 2019-2025
11 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.00 · 2021: $12.79 · 2022: $120 · 2023: $62.56 · 2024: $188 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.14 | 2022-2025 | Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $105.30 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $52.90 | 2019-2023 | Cequa |
| Allergan, INC. | $33.56 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $21.94 | 2022 | |
| Glaukos Corporation | $20.18 | 2022 | |
| Alcon Vision LLC | $19.61 | 2025 | Tryptyr |
| Omeros Corporation | $19.10 | 2019 | |
| Shire North American Group INC | $17.76 | 2019 | |
| Thea Pharma INC. | $15.22 | 2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.